89bio is a clinical-stage biotech focused on liver and cardiometabolic diseases, leveraging fibroblast growth factor 21 (FGF21) biology. Its lead asset, pegozafermin, is an engineered FGF21 analog in Phase 3 trials for MASH and SHTG, targeting significant unmet medical needs. In September 2025, the company announced an agreement to be acquired by Roche, marking a pivotal strategic exit.
Liver DiseasesCardiometabolic Diseases
Technology Platform
Glycopegylated FGF21 analog engineering platform designed to create long-acting versions of the fibroblast growth factor 21 hormone.
Funding History
8
Total raised:$786M
PIPE$150MRA Capital Management
PIPE$150MRA Capital Management
IPO$126MUndisclosed
IPO$120MUndisclosed
Opportunities
The acquisition by Roche provides immense resources for global Phase 3 development and potential commercialization of pegozafermin.
The large, underserved patient populations in MASH and SHTG represent multi-billion dollar market opportunities for a successful therapy.
Risk Factors
Key risks include Phase 3 clinical trial failure, emergence of competitive therapies in the crowded MASH and cardiometabolic spaces, and regulatory hurdles for approval.
Post-acquisition, integration into Roche's portfolio and strategic prioritization are also factors.
Competitive Landscape
The MASH and SHTG therapeutic landscapes are highly competitive. In MASH, 89bio/Roche competes with other late-stage companies like Madrigal (approved resmetirom), Akero, and Viking, among others. In SHTG, competitors include established fibrates, omega-3 prescriptions, and novel agents in development.
